Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. August 2021 16:04 ET | Quelle: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH

NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
10. Juni 2021 02:00 ET | Quelle: Biotalys

Biotalys Nominates Catherine Moukheibir to its Board of Directors

Ghent, BELGIUM, June 10, 2021 (GLOBE NEWSWIRE) -- Biotalys Nominates Catherine Moukheibir to its Board of Directors Highly respected finance and life sciences professional to chair company’s Audit...
21. Juli 2019 06:03 ET | Quelle: ORPHAZYME A/S

Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
18. Juli 2019 01:00 ET | Quelle: ORPHAZYME A/S

Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis

Orphazyme A/SCompany announcement No. 17/2019 ...
07. Juni 2019 00:56 ET | Quelle: ORPHAZYME A/S

Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement No....
10. August 2018 12:19 ET | Quelle: ORPHAZYME A/S

Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS

Orphazyme A/SCompany announcement No....
15. Dezember 2017 09:20 ET | Quelle: ORPHAZYME A/S

Orphazyme assumes sponsorship of Phase II/III sIBM trial

Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...